Citigroup Inc. raised its position in shares of Athenex Inc (NASDAQ:ATNX) by 879.5% in the first quarter, HoldingsChannel.com reports. The fund owned 26,270 shares of the company’s stock after acquiring an additional 23,588 shares during the period. Citigroup Inc.’s holdings in Athenex were worth $447,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently modified their holdings of the company. Private Advisor Group LLC boosted its holdings in shares of Athenex by 47.5% during the first quarter. Private Advisor Group LLC now owns 15,266 shares of the company’s stock worth $260,000 after acquiring an additional 4,915 shares during the period. KCS Wealth Advisory bought a new stake in shares of Athenex during the first quarter worth approximately $179,000. Deutsche Bank AG boosted its holdings in shares of Athenex by 190.8% during the fourth quarter. Deutsche Bank AG now owns 18,511 shares of the company’s stock worth $293,000 after acquiring an additional 12,146 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Athenex by 30.5% during the first quarter. Alps Advisors Inc. now owns 83,874 shares of the company’s stock worth $1,427,000 after acquiring an additional 19,609 shares during the period. Finally, Virtus Fund Advisers LLC bought a new stake in shares of Athenex during the fourth quarter worth approximately $333,000. Institutional investors own 16.63% of the company’s stock.
Shares of ATNX stock opened at $19.02 on Tuesday. Athenex Inc has a 1 year low of $13.16 and a 1 year high of $20.79.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Monday, May 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The company had revenue of $37.84 million during the quarter. Athenex had a negative net margin of 136.72% and a negative return on equity of 75.45%. equities research analysts predict that Athenex Inc will post -1.36 EPS for the current fiscal year.
In other Athenex news, insider Jeffrey Yordon bought 5,000 shares of the business’s stock in a transaction on Monday, March 26th. The stock was purchased at an average cost of $14.69 per share, for a total transaction of $73,450.00. Following the completion of the purchase, the insider now directly owns 188,709 shares of the company’s stock, valued at $2,772,135.21. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Jinn Wu bought 10,000 shares of the business’s stock in a transaction on Monday, March 26th. The shares were acquired at an average price of $14.66 per share, with a total value of $146,600.00. Following the completion of the purchase, the director now directly owns 259,208 shares of the company’s stock, valued at $3,799,989.28. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 29,500 shares of company stock valued at $433,850 and sold 301,392 shares valued at $5,041,671. Insiders own 29.50% of the company’s stock.
A number of brokerages have recently issued reports on ATNX. BidaskClub upgraded Athenex from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 11th. ValuEngine upgraded Athenex from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Zacks Investment Research upgraded Athenex from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research note on Tuesday, April 10th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $26.71.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.